Is Beta Bionics, Inc. (BBNX) a Buy, Sell, or Hold?

Enter your email address below for free access to our Beta Bionics, Inc. (BBNX) research center and poll results.

NASDAQ : BBNX

Beta Bionics, Inc.

$16.79 USD

-$0.11 (-0.65%)

Volume: 867.26K
Average Volume: 951.13K
Market Capitalization: $748.19M
P/E Ratio: -11.11
Dividend Yield: 0.00%
Price Target: $20.00

Year High: $32.71
Year Low: $8.80
Day High: —
Day Low: —
Payout Ratio: $0.00
Current Ratio: $10.69

Price Target and Rating

Average Stock Price Forecast	$20.00
High Stock Price Forecast	$24.00
Low Stock Price Forecast	$14.00
Forecast Upside/Downside	-16.05%
Consensus Rating	Sell
Rating Score(0-5)	2
Research Coverage	8 Analysts

Profitability

EPS (Most Recent Fiscal Year)	-$1.81
Trailing P/E Ratio	-11.11
PEG Ratio	-0.15
P/E Growth	-0.15
Net Income	-$73.2M
Net Margin	-60.27%
Pretax Margin	-60.27%
Return on Equity	-23.00%
Return on Assets	-21.82%

Financials Score

AltmanZ Score	12.32
Piotroski Score	2.00
Working Capital	224.8M
Total Assets	304.42M
Ebit	-66.44M
Market Cap	751.31M
Total Liabilities	33.17M

Poll Results

About Beta Bionics, Inc. (NASDAQ:BBNX) Stock

Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To suppor ... t its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.

Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders

2026-07-01 11:28:00

SAN DIEGO, July 1, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026

2026-07-01 08:30:00

IRVINE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its second quarter 2026 financial results after the financial markets close on Wednesday, July 29, 2026.

Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders

2026-06-29 10:31:24

SAN DIEGO, June 29, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders

2026-06-29 10:31:00

Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders

2026-06-22 12:15:00

SAN DIEGO, June 22, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders

2026-06-17 12:06:44

SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders

2026-06-17 12:06:00

Johnson Fistel Continues Investigation of Beta Bionics, Inc. (BBNX)

2026-06-15 11:00:00

Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concer

Frequently Asked Questions

What is the current Beta Bionics, Inc. (BBNX) stock price?: Beta Bionics, Inc.(NASDAQ:BBNX) stock price is $16.79 in the last trading session. During the trading session, BBNX stock reached the peak price of $32.71 while $8.8 was the lowest point it dropped to. The percentage change in BBNX stock occurred in the recent session was --0.65% while the dollar amount for the price change in BBNX stock was -$0.11.
BBNX's industry and sector of operation?: The NASDAQ listed BBNX is part of Medical - Equipment & Services industry that operates in the broader Healthcare sector.
Who are the executives of BBNX?: Blake Beber | Head of Investor Relations
Steven Russell | Chief Medical Officer
David Henderson | Vice President of Operations
Mark Hopman | Chief Commercial Officer
Mike Mensinger | Chief Product Officer
How many employees does BBNX have?: Number of BBNX employees currently stands at 423. BBNX operates from 11 Hughes, Irvine, CA 92618, US.

Link for BBNX official website?: Official Website of BBNX is: https://www.betabionics.com
How do I contact BBNX?: BBNX could be contacted at phone #949 427 7785 and can also be accessed through its website. BBNX operates from 11 Hughes, Irvine, CA 92618, US.
How many shares of BBNX are traded daily?: The average number of BBNX shares traded daily for last 3 months was 951.13K.
What is the market cap of BBNX currently?: The market value of BBNX currently stands at $748.19M with its latest stock price at $16.79

Enter your email address below for free access to our Beta Bionics, Inc. (BBNX) research center and poll results.

Beta Bionics, Inc.

$16.79 USD

Company Overview

Liquidity Metrics

Sales & Valuation

Profitability

P/E Metrics

Analyst Price Target & Rating

Poll Results